The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, it is considered a new potential target for cancer immunotherapy [19,21].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [21]
In the citing paper
“However, recent studies have revealed the intrinsic expression of PD-1 in many cancers, along with immune T cells [20,21].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [21]
In the citing paper
“Recent studies have revealed the intrinsic expression of PD-1 in many cancers, along with T immune cells [20,21].”
From Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
PD-1 expression on dendritic cells suppresses CD8+T cell function and antitumor immunity
Lim, T. S., Chew, V., Sieow, J. L., Goh, S., Yeong, J. P.-S., Soon, A. L., & Ricciardi-Castagnoli, P. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1085146 · Cited by 184 · cited 1×
“Programmed cell death protein 1 (PD-1) is expressed by both lymphoid(2) and non-lymphoid immune cells,(3,4) and is up-regulated upon after engagement of T cell or B cell receptors on na€ıve lymphocytes.(2,4) Activation of PD-1 by its ligand PD-L1 induces down-regulation of lymphocyte proliferation and cytokine product…”
Background
Flagged first, then by citations
Research works printed but not linked: 51
- 10.3322/caac.21262 · DOI
- 10.1111/j.1600-065X.2010.00923.x · DOI · Paper page
- 10.1158/1078-0432.CCR-06-2746 · DOI · Paper page
- 10.1007/s10549-014-2988-5 · DOI
- 10.1073/pnas.0406351101 · DOI · Paper page
- 10.1056/NEJMoa1200690 · DOI · Paper page
- 10.1056/NEJMoa1500596 · DOI · Paper page
- 10.1002/ijc.30869 · DOI
- 10.1002/ijc.30138 · DOI
- 10.1007/s40291-016-0188-1 · DOI
- 10.1186/s12943-016-0539-x · DOI
- 10.1016/j.ejca.2013.02.015 · DOI
- 10.1007/s00262-017-1999-6 · DOI
- 10.1038/modpathol.2016.139 · DOI · Paper page
- 10.1080/2162402X.2017.1331194 · DOI
- 10.1016/j.ejca.2016.06.015 · DOI
- 10.1016/j.ejso.2014.11.001 · DOI
- 10.1002/jso.20156 · DOI
- Hansen IO, 2012, Dan Med J, 59, A4444
- 10.1016/j.ejca.2016.10.007 · DOI · Paper page
- 10.1016/j.clcc.2016.09.010 · DOI
- 10.1093/annonc/mdx119 · DOI
- 10.1093/annonc/mdx175 · DOI
- Frey DM, 2010, Int J Cancer, 126, 2635, 10.1002/ijc.24989 · DOI
- 10.1200/JCO.2008.18.7229 · DOI
- 10.1038/srep36956 · DOI
- 10.1016/j.ygyno.2016.03.008 · DOI
- 10.18632/oncotarget.14519 · DOI
- 10.1158/1078-0432.CCR-06-2599 · DOI · Paper page
- 10.1073/pnas.192461099 · DOI
- 10.1038/nature14011 · DOI · Paper page
- 10.1158/1078-0432.CCR-13-3271 · DOI · Paper page
- 10.1084/jem.20160801 · DOI
- 10.1080/2162402X.2017.1294299 · DOI
- 10.1158/2326-6066.CIR-16-0391 · DOI
- 10.1038/nature13904 · DOI
- 10.1136/gutjnl-2016-311421 · DOI
- 10.1038/modpathol.2016.95 · DOI
- 10.1038/modpathol.2017.59 · DOI
- 10.18632/oncotarget.19318 · DOI
- 10.18632/oncotarget.6429 · DOI
- 10.1158/0008-5472.CAN-12-2606 · DOI
- 10.1136/gutjnl-2011-300865 · DOI
- 10.1631/jzus.B0820273 · DOI
- 10.1038/srep20090 · DOI
- 10.1016/j.molimm.2007.08.013 · DOI
- 10.1038/bjc.2011.295 · DOI
- 10.1038/bjc.2012.34 · DOI
- 10.1111/j.1365-2796.1993.tb00647.x · DOI
- 10.1186/1746-1596-8-10 · DOI
- 10.1186/2042-6410-4-17 · DOI
Cited by
Sorted by citations
AbouAitah, K., Hassan, H. A., Swiderska-Sroda, A., Gohar, L., Shaker, O. G., Wojnarowicz, J., Opalinska, A., Smalc-Koziorowska, J., Gierlotka, S., & Lojkowski, W. (2020) · Cancers · doi:10.3390/cancers12010144 · Cited by 105
Metadata
- Authors
- Berntsson, J., Eberhard, J., Nodin, B., Leandersson, K., Larsson, A. H., & Jirström, K.
- Affiliations
- Department of Clinical Sciences Lund, Oncology and Pathology, Lund University, Lund, Sweden
- Cancer Immunology, Department of Translational Medicine, Lund University, Malmö, Sweden
- ORCID
- Berntsson, Jonna
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2018-05-02
- Pages
- e1465165
- ISSN
- 2162-402X
- PMC
- PMC6136864
- Cited by
- 62
- References
- 7
- Language
- en
- Funders
- Swedish Cancer Society (CAN 2016/483)
- Swedish Research Council (2015-03598)
- Swedish Government Grant for Clinical Research
- Mrs Berta Kamprad Foundation
- University Hospital Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
